This study is in progress, not accepting new patients

Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease

a study on Autosomal Dominant Polycystic Kidney Disease Kidney Disease

Summary

Eligibility
for people ages 12-65 (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
study ends around
Principal Investigator
by Meyeon Park
Headshot of Meyeon Park
Meyeon Park

Description

Summary

The purpose of this study is to estimate the prevalence, demographic, and clinical characteristics of PKD1/2 gene variant groups in the ADPKD population.

Official Title

A Study to Determine the Prevalence and Clinical Characteristics Associated With PKD1 Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Keywords

Autosomal Dominant Polycystic Kidney Disease (ADPKD), ADPKD, Autosomal Dominant Polycystic Kidney

Eligibility

You can join if…

Open to people ages 12-65

  • Estimated glomerular filtration rate (eGFR) greater than or equal to (≥) 30 milliliter per minute (mL/min)/1.73 m2
  • Willing and able to comply with scheduled visits and other study procedures
  • A pre-existing diagnosis of ADPKD as defined in the protocol

You CAN'T join if...

  • History of kidney disease other than ADPKD that in the opinion of the investigator would independently impact the natural history of ADPKD
  • History of solid organ or bone marrow transplantation or nephrectomy
  • Ongoing renal replacement therapy or planning to start renal replacement therapy less than or equal to (≤)12 months from the Genotyping Visit in Part A

Other protocol defined Inclusion/Exclusion criteria will apply.

Locations

  • Helen Diller Medical Center at Parnassus Heights
    San Francisco California 94143 United States
  • Kaiser Permanente - Los Angeles Medical Center
    Los Angeles California 90027 United States

Lead Scientist at UCSF

  • Meyeon Park
    My research focuses on patient outcomes in genetic kidney diseases including polycystic kidney disease and APOL1-mediated kidney disease. I am the medical director of the UCSF PKD Center of Excellence and principal investigator of the UCSF Cardiovascular Risk After Kidney Transplantation (CARAKTER) study.

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Vertex Pharmaceuticals Incorporated
ID
NCT06747572
Study Type
Observational
Participants
About 401 people participating
Last Updated